» Articles » PMID: 22128330

Intraprotomer Masking of Third Variable Loop (V3) Epitopes by the First and Second Variable Loops (V1V2) Within the Native HIV-1 Envelope Glycoprotein Trimer

Overview
Specialty Science
Date 2011 Dec 1
PMID 22128330
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Within the trimeric HIV-1 envelope (Env) spike, the first and second variable loops (V1V2 region) and the third variable loop (V3) of the gp120 subunit play dual roles in antibody recognition, because they contain neutralization epitopes and also participate in epitope masking. The spatial relationships between V1V2 and V3 and the associated mechanisms of epitope masking remain unclear. Here we investigated interactions between these domains using two monoclonal antibodies recognizing distinct conserved linear epitopes that are subject to masking in the functional trimer, which limits their neutralizing activities. Using Env pseudotype virus infection assays, we found that deleting the V1V2 region greatly enhanced neutralization by both antibodies, leading us to consider two alternative models: V1V2 on one gp120 protomer masks V3 on the same protomer (intraprotomer or cis masking) versus on an adjacent protomer (interprotomer or trans masking). Our experimental approach exploited a previously described complementation system wherein two variant Envs harboring different inactivating mutations (one in gp120, the other in gp41) are coexpressed in the same cell; functional Env results only from cooperative interactions within mixed trimers, thereby enabling selective examination of mixed trimer activity. We introduced additional mutations that either promoted (V1V2 deletion, i.e., unmasking) or prevented (GPGR to GPGQ mutation, i.e., epitope destruction) interaction with the antibodies. The observed neutralization sensitivities of mixed trimers produced from various combinations of constructs support the intraprotomer (cis) model of V1V2 masking of V3 epitopes.

Citing Articles

Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization.

Glogl M, Friedrich N, Cerutti G, Lemmin T, Kwon Y, Gorman J Nat Struct Mol Biol. 2023; 30(9):1323-1336.

PMID: 37605043 PMC: 10497408. DOI: 10.1038/s41594-023-01062-z.


Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection.

Shipley M, Prasad V, Doepker L, Dingens A, Ralph D, Harkins E Elife. 2021; 10.

PMID: 34263727 PMC: 8376252. DOI: 10.7554/eLife.68110.


Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State.

Zhang P, Kwon A, Guzzo C, Liu Q, Schmeisser H, Miao H mBio. 2021; 12(2).

PMID: 33785631 PMC: 8092198. DOI: 10.1128/mBio.00090-21.


Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Beltran-Pavez C, Ferreira C, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M PLoS One. 2018; 13(12):e0208345.

PMID: 30566493 PMC: 6300218. DOI: 10.1371/journal.pone.0208345.


Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation.

Guzzo C, Zhang P, Liu Q, Kwon A, Uddin F, Wells A mBio. 2018; 9(6).

PMID: 30538178 PMC: 6299476. DOI: 10.1128/mBio.00955-18.


References
1.
Gorny M, Stamatatos L, Volsky B, Revesz K, Williams C, Wang X . Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol. 2005; 79(8):5232-7. PMC: 1069558. DOI: 10.1128/JVI.79.8.5232-5237.2005. View

2.
Zolla-Pazner S, Cardozo T . Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol. 2010; 10(7):527-35. PMC: 3167078. DOI: 10.1038/nri2801. View

3.
Dey A, David K, Lu M, Moore J . Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology. 2009; 385(1):275-81. PMC: 3795524. DOI: 10.1016/j.virol.2008.12.009. View

4.
Moore P, Crooks E, Porter L, Zhu P, Cayanan C, Grise H . Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006; 80(5):2515-28. PMC: 1395414. DOI: 10.1128/JVI.80.5.2515-2528.2006. View

5.
Krachmarov C, Honnen W, Kayman S, Gorny M, Zolla-Pazner S, Pinter A . Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol. 2006; 80(14):7127-35. PMC: 1489036. DOI: 10.1128/JVI.02619-05. View